Health IT

Herbs, Etc. just won Superfood of the Year. We explore how a legacy brand uses 57 years of integrity to innovate and thrive in today's crowded market.

A new FDA-approved therapy from Boehringer Ingelheim and a liquid biopsy from Guardant Health offer the first targeted initial treatment for HER2-mutant NSCLC.

Amidst a wave of new legislation, a Miami luncheon brings lawyers and lawmakers together, revealing how direct engagement is shaping Florida's civil justice system.

With $850M in new capital, Base10 Partners doubles down on its 'Real Economy AI' thesis, proving that automating traditional industries is venture's next frontier.

Co-Diagnostics leverages its COVID-19 success for a strategic push into Latin America, aiming to bring rapid PCR testing for a host of diseases to Mexico.

As Canada ages, one annual pitch contest reveals its true intent: not just to award ideas, but to strategically build a national AgeTech ecosystem.

In a bold strategic move, ivari is bundling on-demand healthcare with life insurance, signaling a market shift from passive protection to proactive wellness.

Major academic centers no longer hold a monopoly on medical breakthroughs. A look at how community networks are democratizing cutting-edge cancer research.

New data on an all-oral combo therapy for AML shows remarkable efficacy, offering new hope for patients and cementing Syndax's competitive advantage.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

Philip Morris International holds its dividend steady, signaling stability to investors. But can consistent payouts mask the risks of its smoke-free revolution?

Sun Life's Jacques Goulet brings a background in risk management and a proven record of philanthropic impact to his new role as Chair of the MHIF.

A key deal locking in generic drug prices is extended, promising billions in savings for healthcare and providing crucial stability for a fragile industry.

A key clinical trial completion in Japan signals a major shift in prostate cancer care, heralding the arrival of advanced PSMA-targeted theranostics.

New research shows play instantly bonds families. For confectioner Kinder, it's also a savvy move to capture the lucrative family wellness market.

A Swedish firm's novel cell therapy is the first of its kind in Europe, challenging the grim prognosis of pancreatic cancer and testing a new model for biotech.

Belgium's public sector embraces Google Cloud, navigating a complex path between AI-driven innovation and the strict demands of European data sovereignty.

Nancy Torres analyzes Héma-Québec's summer tour, revealing a sophisticated strategy to combat supply chain risks, secure plasma independence, and diversify its donor base.

Hainan's new medical tourism hub is more than a hospital—it's a strategic play for global dominance, using exclusive drugs and VIP service to lure patients.

Athletes are ditching complex supplement stacks for all-in-one EAA formulas. We explore the science and the industry shift fueling this minimalist movement.